414 related articles for article (PubMed ID: 25548993)
21. IRF4 gene rearrangements define a subgroup of CD30-positive cutaneous T-cell lymphoma: a study of 54 cases.
Pham-Ledard A; Prochazkova-Carlotti M; Laharanne E; Vergier B; Jouary T; Beylot-Barry M; Merlio JP
J Invest Dermatol; 2010 Mar; 130(3):816-25. PubMed ID: 19812605
[TBL] [Abstract][Full Text] [Related]
22. Complete remission of refractory, ulcerated, primary cutaneous CD30+ anaplastic large cell lymphoma following brentuximab vedotin therapy.
Patsinakidis N; Kreuter A; Moritz RK; Stücker M; Altmeyer P; Möllenhoff K
Acta Derm Venereol; 2015 Feb; 95(2):233-4. PubMed ID: 24733422
[No Abstract] [Full Text] [Related]
23. Cytologic evaluation of lymphadenopathy associated with mycosis fungoides and Sezary syndrome: role of immunophenotypic and molecular ancillary studies.
Pai RK; Mullins FM; Kim YH; Kong CS
Cancer; 2008 Oct; 114(5):323-32. PubMed ID: 18798522
[TBL] [Abstract][Full Text] [Related]
24. Detection of clonal T-cell receptor gamma gene rearrangements with the use of the polymerase chain reaction in cutaneous lesions of mycosis fungoides and Sézary syndrome.
Bachelez H; Bioul L; Flageul B; Baccard M; Moulonguet-Michau I; Verola O; Morel P; Dubertret L; Sigaux F
Arch Dermatol; 1995 Sep; 131(9):1027-31. PubMed ID: 7661604
[TBL] [Abstract][Full Text] [Related]
25. CD25+ folliculotropic Sézary syndrome with CD30+ large cell transformation.
Jang MS; Kang DY; Han SH; Park JB; Kim ST; Suh KS
Australas J Dermatol; 2014 Feb; 55(1):e4-8. PubMed ID: 23190349
[TBL] [Abstract][Full Text] [Related]
26. Localized perineal cutaneous nodules: a case of recurrent systemic anaplastic large-cell lymphoma.
Hernandez C; Puangsuvan SN; Peterson A; Robinson JK
Clin Exp Dermatol; 2009 Dec; 34(8):e722-5. PubMed ID: 20055841
[TBL] [Abstract][Full Text] [Related]
27. Reduction of regulatory T cells by Mogamulizumab, a defucosylated anti-CC chemokine receptor 4 antibody, in patients with aggressive/refractory mycosis fungoides and Sézary syndrome.
Ni X; Jorgensen JL; Goswami M; Challagundla P; Decker WK; Kim YH; Duvic MA
Clin Cancer Res; 2015 Jan; 21(2):274-85. PubMed ID: 25376389
[TBL] [Abstract][Full Text] [Related]
28. Durable clinical, cytogenetic, and molecular remissions after allogeneic hematopoietic cell transplantation for refractory Sezary syndrome and mycosis fungoides.
Molina A; Zain J; Arber DA; Angelopolou M; O'Donnell M; Murata-Collins J; Forman SJ; Nademanee A
J Clin Oncol; 2005 Sep; 23(25):6163-71. PubMed ID: 16135483
[TBL] [Abstract][Full Text] [Related]
29. Localization of clonal T cells to the epidermis in cutaneous T-cell lymphoma.
Fivenson DP; Hanson CA; Nickoloff BJ
J Am Acad Dermatol; 1994 Nov; 31(5 Pt 1):717-23. PubMed ID: 7929915
[TBL] [Abstract][Full Text] [Related]
30. A case of mycosis fungoides after CD30 positive anaplastic large cell lymphoma.
Lee MW; Chi DH; Choi JH; Sung KJ; Moon KC; Koh JK
J Dermatol; 2000 Jul; 27(7):458-61. PubMed ID: 10935344
[TBL] [Abstract][Full Text] [Related]
31. Diagnostic and prognostic evaluation of phenotypic markers TRAF1, MUM1, BCL2 and CD15 in cutaneous CD30-positive lymphoproliferative disorders.
Benner MF; Jansen PM; Meijer CJ; Willemze R
Br J Dermatol; 2009 Jul; 161(1):121-7. PubMed ID: 19416236
[TBL] [Abstract][Full Text] [Related]
32. [Clinicopathological differential diagnosis of mycosis fungoides/Sézary syndrome from the cutaneous type of adult T-cell leukemia/lymphoma].
Johno M; Ono T
Nihon Rinsho; 2000 Mar; 58(3):660-4. PubMed ID: 10741142
[TBL] [Abstract][Full Text] [Related]
33. Transformed mycosis fungoides: clinicopathological features and outcome.
Barberio E; Thomas L; Skowron F; Balme B; Dalle S
Br J Dermatol; 2007 Aug; 157(2):284-9. PubMed ID: 17573879
[TBL] [Abstract][Full Text] [Related]
34. Differential patterns of CXCR3, CCR3, and CCR10 expression in mycosis fungoides, Sezary syndrome and CD30(+) lymphoproliferative disorders: immunohistochemical study of 43 samples.
Suga H; Sugaya M; Miyagaki T; Ohmatsu H; Fujita H; Asano Y; Tada Y; Kadono T; Sato S
J Dermatol Sci; 2011 Nov; 64(2):142-4. PubMed ID: 21868202
[No Abstract] [Full Text] [Related]
35. Clinicopathologic and immunologic features associated with transformation of mycosis fungoides to large-cell lymphoma.
Cerroni L; Rieger E; Hödl S; Kerl H
Am J Surg Pathol; 1992 Jun; 16(6):543-52. PubMed ID: 1599034
[TBL] [Abstract][Full Text] [Related]
36. CD30+ neoplasms of the skin.
Duvic M
Curr Hematol Malig Rep; 2011 Dec; 6(4):245-50. PubMed ID: 21850406
[TBL] [Abstract][Full Text] [Related]
37. Upregulation of inhibitory signaling receptor programmed death marker-1 (PD-1) in disease evolution from cutaneous lymphoid dyscrasias to mycosis fungoides and Sezary's syndrome.
Nguyen GH; Olson LC; Magro CM
Ann Diagn Pathol; 2017 Jun; 28():54-59. PubMed ID: 28648940
[TBL] [Abstract][Full Text] [Related]
38. Acquisition of CD30 and CD15 accompanied with simultaneous loss of all pan-T-cell antigens in a case of histological transformation of mycosis fungoides with involvement of regional lymph node: an immunophenotypic alteration resembling classical Hodgkin lymphoma.
Reddi DM; Sebastian S; Wang E
Am J Dermatopathol; 2015 Mar; 37(3):249-53. PubMed ID: 23612034
[TBL] [Abstract][Full Text] [Related]
39. Toll-like receptors 2, 4 and 9 expression in cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome).
Jarrousse V; Quereux G; Marques-Briand S; Knol AC; Khammari A; Dreno B
Eur J Dermatol; 2006; 16(6):636-41. PubMed ID: 17229603
[TBL] [Abstract][Full Text] [Related]
40. Practical Management of CD30⁺ Lymphoproliferative Disorders.
Hughey LC
Dermatol Clin; 2015 Oct; 33(4):819-33. PubMed ID: 26433852
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
